Work

Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL

Year: 2018

Type: letter

Source: Blood

DOI: 10.1182/blood-2018-06-857714

Authors: Jennifer R. Brown, Susan O’Brien, C. Daniel Kingsley, Herbert Eradat, John M. Pagel, Jamie Hirata, Tammy McIver, Rodica Morariu-Zamfir, Thomas J. Kipps

Institutions: UC San Diego Health System, Dana-Farber Cancer Institute, Moores Cancer Center, The University of Texas MD Anderson Cancer Center, Clearview Cancer Institute, University of California, Los Angeles, University of Washington, Fred Hutch Cancer Center, Genentech, Roche (United Kingdom), F. Hoffmann-La Roche AG

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2907383716

Cites: 15

Cited by: 8

Related to: 10